Oncolytics Biotech Reports 3-4x Improvement in Response Duration for RAS-Mutant Colorectal Cancer
Event summary
- Oncolytics Biotech reported a 19.5-month median duration of response in second-line KRAS-mutant MSS mCRC patients, a 3-4x improvement over historical benchmarks of 4-6 months.
- The REO 022 study showed a 33% objective response rate for patients receiving pelareorep, bevacizumab, and FOLFIRI, tripling the 6-11% response rate of standard care.
- Oncolytics is engaging with the FDA to discuss a potential accelerated approval pathway based on response durability and time-to-event endpoints.
- The company is currently enrolling patients in a randomized Phase 2 study for second-line RAS-mutant MSS mCRC.
The big picture
Oncolytics Biotech's data suggest a significant advancement in treating RAS-mutant MSS colorectal cancer, a population with limited effective options. The durability of response observed with pelareorep-based combinations could position the therapy as a potential new standard of care in this setting, pending regulatory approval. The colorectal cancer market remains one of the largest in oncology, with substantial unmet need in later-line settings.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the durability data as sufficient for an accelerated approval pathway in second-line RAS-mutant MSS mCRC.
- Clinical Execution
- The pace at which Oncolytics can enroll and complete its randomized Phase 2 study to support regulatory filings.
- Commercial Strategy
- How Oncolytics plans to leverage these data to attract potential strategic partners for pelareorep's development and commercialization.
Related topics